Pharmacovigilance in Perspective

被引:0
|
作者
Ronald H. B. Meyboom
Antoine C. G. Egberts
Frank W. J. Gribnau
Yechiel A. Hekster
机构
[1] Netherlands Pharmacovigilance Foundation LAREB,Department of Pharmacoepidemiology and Pharmacotherapy
[2] Utrecht University,Department of Clinical Pharmacology
[3] TweeSteden Ziekenhuis,Department of Clinical Pharmacy
[4] Nijmegen University Hospital St Radboud,undefined
[5] Nijmegen University Hospital St Radboud,undefined
[6] The Uppsala Monitoring Centre,undefined
来源
Drug Safety | 1999年 / 21卷
关键词
Adis International Limited; Adverse Drug Reaction; Spontaneous Reporting; Drug Regulation; Pharmacovigilance Centre;
D O I
暂无
中图分类号
学科分类号
摘要
Pharmacovigilance is more than spontaneous reporting alone, and the evaluation of marketed medicines is more than just pharmacovigilance. The positioning of a drug usually takes place during the years following introduction, when worldwide experience has accumulated. Originally a modest appendix of drug regulation, pharmacovigilance has become a major activity. The provision of the information needed for the evaluation of the benefits and risks of drugs is in the first place a scientific challenge. In addition, there are important ethical, logistical, legal, financial and commercial constraints. Good pharmacovigilance practice needs to be developed to ensure that data are collected and used in the right way and for the right purpose.
引用
收藏
页码:429 / 447
页数:18
相关论文
共 50 条
  • [1] Pharmacovigilance in perspective
    Meyboom, RHB
    Egberts, ACG
    Gribnau, FWJ
    Hekster, YA
    [J]. DRUG SAFETY, 1999, 21 (06) : 429 - 447
  • [2] Another Perspective in Pharmacovigilance
    van Puijenbroek, E.
    [J]. DRUG SAFETY, 2015, 38 (10) : 944 - 944
  • [3] Digital Media and Pharmacovigilance: The SIMeF Pharmacovigilance Working Group Perspective
    Stagi, L.
    Bernardini, D.
    Bocchi, I.
    Bonato, S.
    Bottalico, D.
    Calderazzo, V.
    Casino, C.
    Castiglione, G. N.
    Cottone, C.
    Dellon, S.
    Grisoni, I.
    Mattavelli, A.
    Pirisino, G.
    Romano, S.
    Sirizzotti, G.
    [J]. DRUG SAFETY, 2022, 45 (10) : 1178 - 1179
  • [4] HISTORICAL PERSPECTIVE AND FUTURE OF PHARMACOVIGILANCE
    Laporte, J. R.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 6 - 6
  • [5] Intelligent Telehealth in Pharmacovigilance: A Future Perspective
    Heba Edrees
    Wenyu Song
    Ania Syrowatka
    Aurélien Simona
    Mary G. Amato
    David W. Bates
    [J]. Drug Safety, 2022, 45 : 449 - 458
  • [6] Social Media and Pharmacovigilance (an Industry Perspective)
    Lewis, D.
    [J]. DRUG SAFETY, 2017, 40 (10) : 1035 - 1036
  • [7] WHO perspective on pharmacovigilance in developing countries
    Couper, Mary R.
    [J]. TOXICOLOGY LETTERS, 2006, 164 : S27 - S27
  • [8] Pharmacovigilance of herbal medicines - A UK perspective
    Barnes, J
    [J]. DRUG SAFETY, 2003, 26 (12) : 829 - 851
  • [9] Intelligent Telehealth in Pharmacovigilance: A Future Perspective
    Edrees, Heba
    Song, Wenyu
    Syrowatka, Ania
    Simona, Aurelien
    Amato, Mary G.
    Bates, David W.
    [J]. DRUG SAFETY, 2022, 45 (05) : 449 - 458
  • [10] Pharmacovigilance on biologicals and biosimilars: a Danish perspective
    Lunddahl, Benedicte
    [J]. GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2016, 5 (03): : 123 - 124